Board Member
Xenon Pharmaceuticals Inc. (XENE)Chief Accounting Officer
Xenon Pharmaceuticals Inc. (XENE)Equibles does not estimate personal net worth.
Get an email with a short summary when Xenon Pharmaceuticals Inc. publishes a filing, an earnings call transcript or a press release.
Get XENE alertsIan Mortimer is recorded as Chief Accounting Officer at Xenon Pharmaceuticals Inc. (XENE) since June 30, 2025 and CEO and Board Member at Xenon Pharmaceuticals Inc. (XENE). The newest filing on record that lists Ian Mortimer as CEO and Board Member at Xenon Pharmaceuticals Inc. (XENE) is dated April 22, 2026. Xenon Pharmaceuticals Inc. reported in an 8-K filed June 3, 2026 that Ian Mortimer was appointed directors, effective June 2, 2026. Xenon Pharmaceuticals Inc. reported in an 8-K filed July 3, 2025 that Ian Mortimer was appointed principal accounting officer, effective June 30, 2025. Xenon Pharmaceuticals Inc. reported in an 8-K filed July 3, 2025 that Ian Mortimer was appointed interim Chief Financial Officer, effective June 30, 2025. The proxy statement of Xenon Pharmaceuticals Inc. reports total compensation of $9,221,712 for Ian Mortimer in fiscal 2025, including a base salary of $786,000. Disclosed compensation is on record for 9 fiscal years. Ian Mortimer has spoken on 26 earnings calls and 3 other investor events across 1 company, most recently for Xenon Pharmaceuticals Inc. on November 9, 2026. Xenon Pharmaceuticals Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Xenon Pharmaceuticals Inc. includes Simon Pimstone (Chairman), Thomas (Tucker) Kelly (CFO), Thomas Kelly (CFO) and 7 others.
“Ian Mortimer | 86,524,582.53 | | 467,920.65 | | 3,407,133.11”
“On June 30, 2025, the Board of Directors of Xenon Pharmaceuticals Inc. (the "Company") appointed Ian Mortimer, the Company's President and Chief Executive Officer, to the role of interim Chief Financial Officer and designated him as the Company's principal financial officer and principal accounting officer, effective upon the resignation of Sherry Aulin as the Company's Chief Financial Officer on June 30, 2025.”
“We're excited to recap another productive quarter for Xenon as we make continued progress toward becoming a fully integrated neuroscience company, delivering life-changing medicines to patients.”
“We're excited to recap another productive quarter for Xenon as we work toward our goal of becoming a fully integrated neuroscience company, delivering life-changing medicines to patients.”
“Happy to, and good morning, everyone, and thanks, Andrew, for hosting us today. We appreciate it. So for those that are less familiar with the Xenon story, there's really three things that we focus investors on.”
“So I'll take a little bit of a step back and just give a bit of context on is that to calendar and epilepsy, talk through the phase three data. I think you've set it up really nicely.”
“We are excited to recap an exceptional quarter for Xenon, where we made tremendous progress toward our goal of becoming a fully integrated neuroscience company, delivering life-changing medicines to patients.”
2025-06-30–present
Start not stated–present
Last confirmed April 22, 2026
Start not stated–present
Last confirmed April 22, 2026
Start not stated–2021-04-28
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO, Board Member, Chief Accounting Officer
2025-06-30–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Xenon Pharmaceuticals Inc. (XENE) | President and Chief Executive Officer | $786,000 | $9,221,712 |
| 2024 | Xenon Pharmaceuticals Inc. (XENE) | President and Chief Executive Officer | $714,589 | $9,795,347 |
| 2023 | Xenon Pharmaceuticals Inc. (XENE) | President and Chief Executive Officer | $666,018 | $10,117,829 |
| 2022 | Xenon Pharmaceuticals Inc. (XENE) | President and Chief Executive Officer | $594,669 | $9,228,604 |
| 2021 | Xenon Pharmaceuticals Inc. (XENE) | President and Chief Executive Officer | $524,297 | $3,894,997 |
| 2020 | Xenon Pharmaceuticals Inc. (XENE) | President and Chief Executive Officer | $461,970 | $1,783,084 |
| 2019 | Xenon Pharmaceuticals Inc. (XENE) | President and Chief Executive Officer | $420,861 | $1,553,382 |
| 2018 | Xenon Pharmaceuticals Inc. (XENE) | President and Chief Financial Officer | $342,492 | $922,681 |
| 2017 | Xenon Pharmaceuticals Inc. (XENE) | President and Chief Financial Officer, Corporate Secretary | $311,537 | $944,770 |
